To assess MMP-9 involvement in RGC apoptosis, whole retinas, and paraffin-embedded cross sections, stained with annexin V, were also immunostained with sheep anti-MMP-9 (n = 12, 1:250; The Binding Site, Ltd., Birmingham, UK), Cy5-conjugated donkey anti-sheep IgG, and using NF-200 or DiAsp immunofluorescence, to identify RGCs (AffiniPure; Jackson ImmunoResearch). The retinas were examined by confocal laser scanning microscopy and apoptotic RGCs, double-labeled by anti-MMP-9 antibody and annexin V, were counted.
To assess other ECM characteristics at the retina and the ONH, ECM components were studied in sequential 5-μm-thick paraffin-embedded hemiglobe cross sections through the ONH (n = 13) and retina (n = 12), from enucleated, fixed eyes. Primary antibodies used were rabbit anti-laminin (1:60; Chemicon International, Temecula, CA), rabbit anti-collagen type I (1:300; Chemicon International), mouse anti-collagen IV (1:150; Dako A/S, Glostrup, Denmark), sheep anti-MMP1 (1:750, The Binding Site, Ltd.), mouse anti-TIMP-1 (1:20; R&D Systems, Abingdon, UK), and rabbit anti-TGF-β2 (1:500; Santa Cruz Biotechnology Inc., Santa Cruz, CA). A biotinylated anti-sheep and mouse secondary antibody (Dako, High Wycombe, UK), and a biotinylated swine anti-rabbit secondary antibody (Dako) were used accordingly, followed by a tertiary complex antibody (StreptABComplex/HRP; Dako). Cross sections were stained with red dye (Vector Red; Vector Laboratories, Burlingame, CA) or diaminobenzidine (DAB) and counterstained with hematoxylin.
Sections were assessed for staining by two independent and masked observers who used a grading system and analysis method well known to our group,
26 27 28 originally described by Shah et al.
29 (Scale: −4 to +4: where 0 is the same as the control eye, 1 is 1% to 25% of control, 2 is 26% to 50% of control, 3 is 51% to 75% of control, and 4 is >75% of control with the prefix + indicating more than and − less than 0.)